RetLira Retatrutide 30 | Pre-Filled Pen

Lira Pharma RetLira 30mg is a pre-filled multi-dose injection pen labelled as containing 30mg of retatrutide. Retatrutide is an investigational peptide designed as a triple hormone receptor agonist, activating the GIP, GLP-1 and glucagon receptors.

Retatrutide is currently being studied for obesity, type 2 diabetes and related metabolic conditions. It remains investigational and has not yet been approved by regulatory authorities for public use, so its safety and efficacy continue to be evaluated in clinical trials.

What Lira Pharma RetLira 30mg Is Used For

Retatrutide is currently being investigated for its potential role in:

Body-weight reduction in adults with obesity or overweight

Appetite and food-intake regulation

Supporting improvements in metabolic health

Improving blood-glucose control in people with type 2 diabetes

Supporting improvements in certain obesity-related cardiometabolic measures

Clinical trials have demonstrated substantial reductions in body weight, but these findings relate to the investigational retatrutide used in controlled clinical studies and should not be assumed to establish the efficacy of independently manufactured products.

How Lira Pharma RetLira 30mg Works

Retatrutide simultaneously activates three hormone receptors:

GLP-1 receptors – associated with appetite regulation, satiety and glucose-dependent insulin secretion

GIP receptors – involved in metabolic regulation and glucose-dependent insulin responses

Glucagon receptors – involved in energy metabolism and may contribute to increased energy expenditure

This combined GIP, GLP-1 and glucagon receptor activity is what distinguishes retatrutide from single- and dual-receptor incretin therapies.

How to Use Lira Pharma RetLira 30mg

The product shown is presented as a multi-dose pre-filled pen, meaning no separate vial reconstitution is required.

Because retatrutide remains investigational, there is currently no regulator-approved dosing schedule for commercially sold retatrutide products. It should not be self-dosed based solely on non-approved product instructions.

Administration Route: In clinical trials, retatrutide has been administered by subcutaneous injection once weekly.

Dosage Information

Total labelled content per pen: 30mg Retatrutide

The packaging shown provides click-based dosing instructions; however, these are manufacturer-specific instructions for this particular pen and are not an approved retatrutide dosing regimen.

Clinical trials have evaluated different doses and gradual dose-escalation schedules. Appropriate dosing cannot yet be generalized into an approved treatment protocol because retatrutide remains under clinical investigation.

Possible Side Effects

Clinical trials of retatrutide have reported side effects broadly similar to those associated with GLP-1 and GIP/GLP-1 receptor agonists, particularly gastrointestinal effects.

Common

Nausea

Diarrhoea

Vomiting

Constipation

Decreased appetite